The Onychomycosis market growth is driven by factors like increase in the prevalence of Onychomycosis, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Onychomycosis market report also offers comprehensive insights into the Onychomycosis market size, share, Onychomycosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Onychomycosis market size growth forward.
Some of the key highlights from the Onychomycosis Market Insights Report:
Several key pharmaceutical companies, including Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, and others, are developing novel products to improve the Onychomycosis treatment outlook.
The total Onychomycosis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Onychomycosis market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Onychomycosis Market Landscape
Onychomycosis is a fungal nail infection that causes discoloration and thickening of the affected nail plate. It was initially caused by dermatophytes predominantly; however, new research has revealed that mixed infections and those caused by non-dermatophyte molds (NDMs) are more prevalent, especially in warmer climates. Onychomycosis caused by dermatophytes is called tinea unguium. The term Onychomycosis encompasses not only dermatophytes but also yeasts and saprophytic mold infections. It can infect both fingernails and toenails, Onychomycosis of the toenail is more prevalent.
Onychomycosis is classified into subtypes based on the invasion pattern. Distal subungual onychomycosis (DSO) is the most common subtype and occurs when the fungus invades the distal aspect of the nail plate. In superficial white onychomycosis (SWO), fungi invade the most superficial layers of the nail plate. Proximal subungual onychomycosis (PSO) is caused by the infecting organism invading from the undersurface of the proximal nail fold, and the infection then progresses distally. Endonyx onychomycosis (EO) occurs with the fungal invasion of the nail plate without infection of the nail bed. Total dystrophic onychomycosis (TDO) represents end-stage onychomycosis and may follow any other subtypes. Secondary onychomycosis (SO) is a non-fungal nail condition (i.e., psoriasis) with a secondary fungal infection, clinically approximating both the fungal and non-fungal nail conditions.
The treatment of onychomycosis involves the usage of oral antifungals, topical antifungals, and devices. Oral antifungals have higher cure rates than topical treatments but have adverse side effects such as hepatotoxicity and drug interactions. Topical treatments have less serious side effects but generally result in lower cure rates and longer treatment regimens.
Hence, treatment aims to prevent drug interactions and potential hepatotoxicity. The prime focus in the treatment of onychomycosis is to achieve superior efficacy and less time-consuming therapies with better nail bed penetration.
Do you know the treatment paradigms for different countries? Download our Onychomycosis Market Sample Report
Onychomycosis Epidemiology Segmentation
DelveInsight’s Onychomycosis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Onychomycosis historical patient pools and forecasted Onychomycosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Onychomycosis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Age-Specific Onychomycosis Prevalence
Gender-Specific Onychomycosis Prevalence
Diagnosed and Treatable Cases of Onychomycosis
Visit for more @ Onychomycosis Epidemiological Insights
Onychomycosis Treatment Market
The Onychomycosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Onychomycosis market trends by analyzing the impact of current Onychomycosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Onychomycosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Onychomycosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Onychomycosis market in 7MM is expected to witness a major change in the study period 2019-2032.
Onychomycosis Therapy Assessment
MOB‐015: Moberg Pharma
BB2603: Blueberry Therapeutics
Onychomycosis Key Companies
Sato Pharmaceutical, Eisai
For more information, visit Onychomycosis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Onychomycosis Market Report:
11 Years Forecast
Descriptive overview of Onychomycosis, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Onychomycosis epidemiology in the 7MM
Onychomycosis marketed and emerging therapies
Onychomycosis market drivers and barriers
Key Questions Answered in the Onychomycosis Market Report 2032:
What was the Onychomycosis market share distribution in 2019, and how would it appear in 2032?
What is the total Onychomycosis market size and the market size by therapy across the 7MM for the study period (2019-32)?
What are the important findings from 7MM, and which country will have the greatest Onychomycosis market size from 2019-32?
During the study period (2019-2032), at what CAGR is the Onychomycosis market projected to expand at 7MM?
Table of Contents:
1 Onychomycosis Market Key Comprehensive Insights
2 Onychomycosis Market Report Introduction
3 Competitive Intelligence Analysis for Onychomycosis
4 Onychomycosis Market Analysis Overview at a Glance
5 Executive Summary of Onychomycosis
6 Onychomycosis Epidemiology and Market Methodology
7 Onychomycosis Epidemiology and Patient Population
8 Onychomycosis Patient Journey
9 Onychomycosis Treatment Algorithm, Onychomycosis Current Treatment, and Medical Practices
10 Key Endpoints in Onychomycosis Clinical Trials
11 Onychomycosis Marketed Therapies
12 Onychomycosis Emerging Therapies
13 Onychomycosis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Onychomycosis
16 Onychomycosis Market Key Opinion Leaders Reviews
18 Onychomycosis Market Drivers
19 Onychomycosis Market Barriers
20 SWOT Analysis
22 DelveInsight Capabilities
23 About DelveInsight
Onychomycosis Epidemiology 2032
DelveInsight’s “Onychomycosis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Onychomycosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Onychomycosis Pipeline 2023
“Onychomycosis Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Onychomycosis market. A detailed picture of the Onychomycosis pipeline landscape is provided, which includes the disease overview and Onychomycosis treatment guidelines.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States